Trials / Completed
CompletedNCT00389363
Efficacy and Safety Trial of the ALK HDM Tablet in House Dust Mite Allergic Subjects
A Phase II-III Trial Assessing the Efficacy and Safety of Three Doses of the ALK HDM Tablet in House Dust Mite Allergic Patients
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 800 (estimated)
- Sponsor
- ALK-Abelló A/S · Industry
- Sex
- All
- Age
- 14 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the trial is to determine if treatment of asthma patients allergic to house dust mites with the ALK HDM tablet can reduce the need of inhaled corticosteroids (ICS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALK HDM tablet |
Timeline
- Start date
- 2006-08-01
- Primary completion
- 2008-04-01
- Completion
- 2008-04-01
- First posted
- 2006-10-18
- Last updated
- 2010-08-17
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT00389363. Inclusion in this directory is not an endorsement.